Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4084553 | 0.88 | IDO1 (0.42) | IDO1LMNAMAPK13MAPK12MAPK11 | |
| SCHEMBL25699611 | 0.79 | PIK3C3 (0.48) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL7521036 | 0.78 | KDM4E (0.56) | LMNAKMT2AMEN1GAASMN1; SMN2 | |
| SCHEMBL4084091 | 0.78 | CDK2 (0.43) | LMNAMAPK14KMT2AMEN1GAA | |
| SCHEMBL6473915 | 0.77 | NR4A2 (0.46) | KMT2AMEN1POLBPDK1PDK2 | |
| SCHEMBL6033417 | 0.76 | NR4A2 (0.45) | KMT2AMEN1POLBPDK1PDK2 | |
| SCHEMBL4091379 | 0.75 | PTGDR (0.38) | IDO1LMNAMAPK13MAPK12MAPK11 | |
| SCHEMBL4489879 | 0.74 | MEN1 (0.54) | KMT2AMEN1SMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL4816969 | 0.73 | NPC1 (0.39) | LMNAKMT2AMEN1GAASMN1; SMN2 | |
| SCHEMBL6957237 | 0.73 | POLB (0.40) | LMNAKMT2AMEN1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582631-B2 | Paget's disease; muscular disorders; cardiovascular disorders; antiinflamamtory agents; antidiabetic agents; autoimmune disease; leukemia | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582631-B2 | Paget's disease; muscular disorders; cardiovascular disorders; antiinflamamtory agents; antidiabetic agents; autoimmune disease; leukemia | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582631-B2 | Paget's disease; muscular disorders; cardiovascular disorders; antiinflamamtory agents; antidiabetic agents; autoimmune disease; leukemia | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-06-11 | — | — | US | disclosed |
| EP-1727821-A1 | SUBSTITUTED DIAZABICYCLOHEPTANES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Amgen Inc. (US) | 2006-12-06 | — | — | EP | disclosed |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-08-18 | — | — | US | disclosed |
| WO-2005070934-A1 | SUBSTITUTED DIAZABICYCLOHEPTANES AND THEIR USE AS PROTEIN KINASE INHIBITORS | AMGEN INC. (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | HLA-DRB1, PRKDC, NFATC1 | IDO1 105/4885LMNA 3413/4885MAPK13 300/4885 |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | HLA-DRB1, PRKDC, NFATC1 | IDO1 66/4885LMNA 3551/4885MAPK13 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.